AKBA Akebia Therapeutics, Inc.

13.43
-0.42  -3%
Previous Close 13.85
Open 13.80
Price To book 17.55
Market Cap 245.77M
Shares 18,300,000
Volume 321,121
Short Ratio 5.66
Av. Daily Volume 868,278

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 initiated August 2016. NDA filing pending positive data due 2019. Estimate data release mid-2019.
Vadadustat - INNO2VATE
Anemia related to chronic kidney disease who are undergoing dialysis (DD-CKD)
Phase 3 initiated January 2016. NDA filing pending positive data due 2019. Estimate data release mid-2019.
Vadadustat - PRO2TECT
Non-dialysis patients with anemia related to CKD (NDD-CKD)

Latest News

  1. Akebia Therapeutics Names Rita Jain, M.D. as Chief Medical Officer
  2. Akebia Initiates Phase 2 FO2RWARD Study of Vadadustat in Dialysis Patients with Anemia Related to Chronic Kidney Disease Hyporesponsive to Treatment with Erythropoiesis-Stimulating Agents
  3. Four Stocks Moving On Both News And The Charts
  4. Today's Research Reports on Stocks to Watch: Akebia Therapeutics and xG Technology
  5. Why Akebia Therapeutics Stock Is Skyrocketing Today
  6. Biotech Movers: Akebia, Editas, Novavax
  7. Vifor Pharma and Akebia Announce Exclusive License Agreement to Provide Vadadustat to Fresenius Medical Care in the U.S. Upon FDA Approval
  8. Akebia and Vifor Pharma Announce Exclusive License Agreement to Provide Vadadustat to Fresenius Medical Care in the U.S. Upon FDA Approval
  9. Akebia Secures Exclusive Access to U.S. Dialysis Patients With Vifor-Fresenius Pact
  10. Akebia Therapeutics reports 1Q loss
  11. Akebia Announces First Quarter 2017 Financial Results
  12. Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
  13. Akebia Therapeutics, Inc. – Value Analysis (NASDAQ:AKBA) : April 28, 2017
  14. Akebia Therapeutics (AKBA) Shows Strength: Stock Up 5.8%
  15. 4 Things To Know About Akebia's New Vadadustat Collaboration With Otsuka Pharma
  16. Akebia Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : AKBA-US : April 27, 2017
  17. Why Akebia Therapeutics Shares Soared 33.4% Today
  18. Akebia Surges but is Still Undervalued, Making Takeover a Potential Remedy
  19. Biotech Movers: Akebia Soars on Expanded Partnership With Otsuka
  20. Akebia expands anemia drug pact with Japanese firm, lifting shares